AstraZeneca: Aspirin May Be To Blame For Poor Results In Some Brilinta Trial Patients
This article was originally published in The Pink Sheet Daily
Executive Summary
Uncertainty over aspirin usage among a North American subgroup of trial patients continues to raise speculation about an FDA review.
You may also be interested in...
FDA Will Present Brilinta Panel With Alternative Explanation For Negative U.S. Data
FDA reviewers discredit AstraZeneca's suggestion that higher doses of aspirin explain ticagrelor's discordant results for U.S. versus overall trial participants - but also offer an alternative reason for the findings.
FDA Will Present Brilinta Panel With Alternative Explanation For Negative U.S. Data
FDA reviewers discredit AstraZeneca's suggestion that higher doses of aspirin explain ticagrelor's discordant results for U.S. versus overall trial participants - but also offer an alternative reason for the findings.
AstraZeneca's Brilinta: Can Advisory Committee Help Build Momentum?
Antiplatelet ticagrelor will likely confront the "North American anomaly" during its July 28 review by FDA's cardio-renal panel.